Our Pricing

Wegovy vs Mounjaro: Which Weight Loss Injection Works Best?

Choosing between wegovy vs mounjaro uk online options requires understanding how these two leading weight loss injections differ in mechanism, efficacy, and suitability. Both are MHRA-licensed GLP-1 receptor agonists available through Cured Pharmacy after a free clinical assessment by our UK prescribers, but they work through distinct pathways and produce different results in clinical trials.

How Mounjaro and Wegovy Work Differently

Mounjaro (tirzepatide) is the UK's first dual GIP/GLP-1 receptor agonist, activating two complementary hormone pathways that regulate appetite, insulin secretion, and glucose metabolism [1]. This dual mechanism distinguishes it from single-pathway treatments and contributes to its enhanced efficacy profile in clinical trials.

Wegovy (semaglutide) works as a selective GLP-1 receptor agonist, mimicking the glucagon-like peptide-1 hormone that reduces appetite and slows gastric emptying [2]. Both medications are administered as once-weekly subcutaneous injections and require gradual dose escalation to minimise gastrointestinal side effects, which our UK prescribers carefully manage during your treatment journey.

Clinical Trial Results: Mounjaro vs Wegovy Efficacy

In the SURMOUNT-1 trial, patients taking Mounjaro 15mg achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. The lower 10mg dose produced an average 21.1% reduction, whilst the 5mg dose resulted in 15% weight loss on average.

Wegovy demonstrated significant efficacy in the STEP 1 trial, with participants losing an average of 14.9% body weight over 68 weeks on the 2.4mg maintenance dose, compared to 2.4% with placebo [2]. Approximately 50.5% of Wegovy-treated patients achieved at least 15% body weight reduction, versus 4.9% in the placebo group.

Head-to-head comparisons suggest tirzepatide produces greater average weight loss than semaglutide at equivalent treatment durations, though individual responses vary considerably based on adherence, lifestyle modifications, and metabolic factors [3]. Your UK prescriber will assess which medication aligns best with your medical history and weight loss goals during your consultation.

Long-Term Weight Maintenance Considerations

Both medications require ongoing treatment to maintain weight loss, as discontinuation typically results in gradual weight regain [3]. Clinical trials demonstrate that patients who combine these injections with structured dietary changes and increased physical activity achieve superior outcomes compared to medication alone, which is why our clinical team provides comprehensive lifestyle guidance alongside your prescription.

Side Effects and Tolerability Profile

The most common side effects for both Mounjaro and Wegovy are gastrointestinal: nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][2]. These symptoms typically emerge during dose escalation and diminish over several weeks as your body adapts to the medication.

In clinical trials, approximately 6% of Mounjaro patients discontinued treatment due to adverse effects, compared to 7% in Wegovy trials [1][2]. Nausea occurred in 25-30% of patients across both medications, though severity and duration varied considerably between individuals.

Rare but serious risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies but not confirmed in humans) [4]. Both medications carry contraindications for patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, which your UK prescriber will screen for during your clinical assessment.

Managing Side Effects Effectively

Our pharmacist team recommends eating smaller, more frequent meals, avoiding high-fat foods during the initial weeks, and staying well-hydrated to minimise gastrointestinal symptoms. If side effects become troublesome, your prescriber may adjust your dose escalation schedule or recommend temporary dose reduction, ensuring treatment remains tolerable whilst maintaining efficacy.

Dosing Schedules and Administration

Mounjaro treatment begins at 2.5mg weekly for four weeks, then increases to 5mg weekly. If additional weight loss is needed and the medication is well-tolerated, your prescriber may escalate to 7.5mg, 10mg, 12.5mg, or the maximum 15mg dose at four-week intervals [1]. Each dose is administered using a pre-filled KwikPen injector.

Wegovy follows a different escalation pathway: starting at 0.25mg weekly for four weeks, then 0.5mg, 1mg, 1.7mg, and finally the maintenance dose of 2.4mg weekly [2]. The slower titration schedule helps minimise gastrointestinal side effects whilst allowing your body to adapt gradually.

Both injections are administered subcutaneously in the abdomen, thigh, or upper arm, and can be taken at any time of day with or without food. Patients should rotate injection sites weekly to prevent lipodystrophy and ensure consistent absorption, guidance our clinical team provides during your initial consultation.

Who Is Suitable for Mounjaro or Wegovy?

Both medications are licensed in the UK for adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [4]. Your UK prescriber will calculate your BMI and assess comorbidities during your online consultation.

Mounjaro and Wegovy are contraindicated in pregnancy, during breastfeeding, and in patients with severe gastrointestinal disease, diabetic ketoacidosis, or history of medullary thyroid carcinoma [4]. Patients taking certain medications including insulin or sulfonylureas may require dose adjustments to prevent hypoglycaemia, which our prescribers carefully evaluate.

If you have previously tried and discontinued semaglutide due to intolerable side effects, switching to tirzepatide may be appropriate, as some patients tolerate the dual-agonist mechanism differently. Conversely, if cost is a primary concern and you meet clinical criteria, starting with the lower-priced option may be reasonable, with the option to switch if weight loss plateaus or side effects emerge.

When to Consider Alternative Treatments

For patients with lower BMI who don't meet criteria for GLP-1 injections, or those who prefer oral medications, alternatives like Orlistat or Xenical may be more appropriate. Our weight loss category includes multiple evidence-based options, and your prescriber will recommend the treatment most aligned with your clinical profile and preferences.

Accessing Mounjaro and Wegovy Through Cured Pharmacy

Both Mounjaro and Wegovy require a prescription from a UK-registered prescriber, which you can obtain through our free online consultation that typically takes under three minutes to complete. Our clinical team reviews your medical history, current medications, weight loss goals, and any contraindications before determining suitability.

Mounjaro is available at Cured Pharmacy with transparent upfront pricing, and Wegovy starts from a competitive rate compared to typical UK market prices. All medications are genuine UK-licensed products sourced through MHRA-regulated channels, dispensed by our GPhC-registered pharmacy (9012511) under the supervision of Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Once your prescription is approved, we dispatch your medication in 100% discreet packaging with next-day delivery options available across the UK. Our pharmacist team remains available for ongoing support throughout your treatment, answering questions about injection technique, side effect management, and optimising your weight loss results alongside lifestyle modifications.

Ongoing Clinical Monitoring and Support

Regular follow-up assessments ensure your treatment remains safe and effective. Most prescribers recommend reviewing progress every 12 weeks, adjusting doses as needed, and discontinuing treatment if you haven't achieved at least 5% weight loss after 12-16 weeks at the therapeutic dose, in line with NICE guidance [4]. Our clinical team coordinates these reviews and ensures continuous, evidence-based care throughout your weight loss journey.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Rubino, D. M., Greenway, F. L., Khalid, U., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619
4. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875

Information on this page is for educational purposes only and is not medical advice. All prescription treatments including Mounjaro and Wegovy require clinical assessment by a UK-registered prescriber. Individual results may vary, and weight loss outcomes depend on adherence to treatment, dietary modifications, and physical activity. Always consult a qualified healthcare professional before starting any new medication or weight loss programme.